MRI vs MRE for Crohn's Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a new, shorter MRI method to examine the bowel in people with Crohn's Disease. The goal is to determine if this quicker scan is as effective as the standard, longer MRI. The trial involves observing and comparing the results of the two MRI methods. Participants should be over 10 years old, have a confirmed Crohn's Disease diagnosis, and be scheduled for an MRI to monitor their condition. As an unphased trial, this study provides a unique opportunity to contribute to research that could simplify and improve MRI procedures for Crohn's Disease patients.
Do I need to stop my current medications for the trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What prior data suggests that this abbreviated MRE protocol is safe for children and adults with Crohn's Disease?
Research has shown that a shorter version of magnetic resonance enterography (MRE) is safe for checking Crohn's Disease. This type of MRI examines the bowel without using radiation, benefiting long-term health.
Studies comparing the shorter MRE to the regular version have not found any serious side effects. The primary difference is that the shorter MRE takes less time, enhancing patient comfort.
Overall, evidence suggests that the shorter MRE is well-tolerated, with no major safety concerns reported in the studies to date.12345Why are researchers excited about this trial?
Researchers are excited about the abbreviated MRE for Crohn's disease because it offers a faster and potentially more comfortable way to monitor the condition compared to traditional imaging methods like full-length magnetic resonance enterography (MRE). This new approach aims to streamline the imaging process, reducing the time patients spend in the scanner without compromising the quality of the information gathered. By improving patient experience and maintaining accuracy, the abbreviated MRE could become a valuable tool in managing Crohn's disease more efficiently.
What evidence suggests that this abbreviated MRE protocol is effective for Crohn's Disease?
Studies have shown that a shorter version of magnetic resonance enterography (MRE), which participants in this trial will undergo, can effectively detect inflammation and issues in Crohn's disease. This version reduces the scan time from about 19 minutes to 11 minutes, making the process more comfortable for patients without sacrificing accuracy. MRE also helps doctors predict the progression of Crohn's disease over time. Additionally, research shows that when MRE indicates healing and remission, it correlates with better outcomes in children with Crohn's disease. Overall, the shorter MRE offers a promising and faster alternative to traditional methods while maintaining effectiveness.26789
Who Is on the Research Team?
Jonathan Dillman
Principal Investigator
CCHMC
Are You a Good Fit for This Trial?
Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Observation
Participants undergo an abbreviated MRE and complete a trade-off tolerance survey
Follow-up
Participants are monitored for safety and effectiveness after the MRE
What Are the Treatments Tested in This Trial?
Interventions
- Abbreviated MRE
How Is the Trial Designed?
1
Treatment groups
Experimental Treatment
Children and adults, who are scheduled for a clinical magnetic resonance enterography (MRE) to evaluate staging/ restaging of Crohn's disease, will be approached to undergo our novel abbreviated MRE. No intervention, observation only, perform MRE, and complete trade-off tolerance survey.
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor
Citations
Fast Magnetic Resonance Enterography Protocol for the ...
Evaluation time was significantly decreased using the abbreviated MRE protocol compared with full MRE study (median 11 vs. 19 min), with a time ...
Role of abbreviated non-contrast-enhanced MR ...
This study aims to describe and compare these protocols and evaluate their accuracy in detecting active inflammation and CD complications.
Magnetic resonance enterography for predicting poor ...
This systematic review demonstrated that MRE is effective in predicting the prognosis of CD, with significant predictors including inflammation, ...
Proposal of an Abbreviated Noncontrast MR Enterography ...
MR enterography (MRE) protocols used in patients with Crohn disease are burdened by long acquisition time, high cost, and suboptimal patient experience.
Consensus Recommendations
Magnetic resonance enterography heal- ing and magnetic resonance enterography remission predicts improved outcome in pediatric Crohn disease.
Evaluation of Crohn Disease Activity Using a Potential ...
The purpose of the present study was to compare the diagnostic performance of an abbreviated MR enterography (MRE) protocol consisting of balanced steady-state ...
Magnetic Resonance Enterography and Intestinal Ultrasound ...
Studies assessing the accuracy of POCUS in IBD have demonstrated a sensitivity for detecting active disease ranging from 87.5% to 91% and specificity of 61.1% ...
8.
clinicalimagingscience.org
clinicalimagingscience.org/fast-magnetic-resonance-enterography-protocol-for-the-evaluation-of-patients-with-crohns-disease-a-pilot-study/Fast Magnetic Resonance Enterography Protocol for the ...
The aim of our work was to design a “fast” abbreviated MRE protocol and to compare it with the standard one.
Helmsley 3.0: Abbreviated MRE 1. ABSTRACT: MRI of the ...
MRI of the bowel, or MR enterography (MRE), is commonly performed to evaluate children and adults with known or suspected inflammatory bowel ...
Unbiased Results
We believe in providing patients with all the options.
Your Data Stays Your Data
We only share your information with the clinical trials you're trying to access.
Verified Trials Only
All of our trials are run by licensed doctors, researchers, and healthcare companies.